Consensus Invivyd, Inc.

Equities

IVVD

US00534A1025

Market Closed - Nasdaq Other stock markets 21:00:00 30/04/2024 BST			5-day change	1st Jan Change
2.22 ^USD	+6.73%		-2.20%	-43.65%

04-15	Invivyd, Inc. Receives Healthcare Common Procedure Coding System Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services Covering Pemgarda	CI
04-12	Invivyd Names Jeremy Gowler as Interim CEO	MT

Evolution of the average Target Price on Invivyd, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0d4840e5058373b01bf8319b389.WodEnc9GUn2X_vPSICbPXQiG2xVbh3zwBWL7c8536zA.E9YAyfxxNAT7lLmieRWQGmDZqUQ3zj6fTFHDSoEt23wO3zGuggc9McPGlA~e7199cc8bc644a8783905c9e4cb527ad

Analyst Recommendations on Invivyd, Inc.

Guggenheim Upgrades Invivyd to Buy From Hold, Price Target is $9	04-05	MT
Invivyd Receives Upgrade to Overweight From Equalweight From Morgan Stanley, Price Target Raised to $10 From $4 Amid Pemgarda FDA Authorization	03-26	MT
HC Wainwright Raises Price Target on Invivyd to $15 From $5, Keeps Buy Rating	01-18	MT
Morgan Stanley Upgrades Invivyd to Equal-Weight From Underweight, Raises Price Target to $4 From $1	12-19	MT
HC Wainwright Starts Invivyd at Buy With $5 Price Target	01/05/23	MT
Morgan Stanley Adjusts Price Target on Invivyd to $1 From $2, Maintains Underweight Rating	27/03/23	MT
Morgan Stanley Trims Invivyd Price Target to $2 From $3, Maintains Underweight Rating	24/01/23	MT
Stifel Adjusts Adagio Therapeutics' Price Target to $5 From $9, Reiterates Hold Rating	16/05/22	MT
Morgan Stanley Downgrades Adagio Therapeutics to Underweight Rating From Equalweight, Adjusts PT to $6 From $11	06/01/22	MT
Jefferies Downgrades Adagio Therapeutics to Hold From Buy; Price Target is $10	22/12/21	MT
Morgan Stanley Downgrades Adagio Therapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $49	15/12/21	MT
Guggenheim Downgrades Adagio Therapeutics to Neutral From Buy	15/12/21	MT
Stifel Downgrades Adagio Therapeutics to Hold From Buy, Adjusts Price Target to $9 From $50	15/12/21	MT
--Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Target is $49; Shares Surge 70%	29/11/21	MT
Morgan Stanley Upgrades Adagio Therapeutics to Overweight From Equalweight; Price Target is $49	29/11/21	MT
Today on Wall Street: US tech giants return to top spot	31/08/21
ANALYST RECOMMENDATIONS : AT&T, BancorpSouth Bank, CMO Group, Magnite, Textron...	31/08/21
ADAGIO THERAPEUTICS : Morgan Stanley Starts Adagio Therapeutics at Equal-Weight With $33 Price Target	31/08/21	MT
ADAGIO THERAPEUTICS : Jefferies Starts Adagio Therapeutics at Buy With $60 Price Target	31/08/21	MT
ADAGIO THERAPEUTICS : Stifel Starts Adagio Therapeutics at Buy With $57 Price Target	31/08/21	MT
ADAGIO THERAPEUTICS : Guggenheim Starts Adagio Therapeutics at Buy With $40 Price Target	31/08/21	MT